THERMALLY STABLE AND pH STABLE SUBTILISIN ANALOGS AND METHOD FOR PRODUCTION THEREOF

Abstract: A mutated subtilisin suitable for admixture to washing compositions and exhibiting substantially improved stability over naturally occuring Bacillus serine proteases is prepared by expressing a modified gene encoding subtilisin in Bacillus subtilis. A preferred subtilisin analog product differs from wild-type Bacillus alkaline proteases by having any amino acid, and preferably serine, at position (218) in place of asparagine. The product is preferably produced in a strain of B. subtilis which is mutated to block synthesis of endogenous proteases. The method of replacing an Asn or Gly in an Asn-Gly sequence in order to improve pH and thermal stability may be applied to other sites in substilisin and to other proteins as well.

Description: THERMALLY STABLE AND pH STABLE SUBTILISIN ANALOGS AND METHOD FOR PRODUCTION THEREOF Background of the Invention The present invention relates in general to thermally stable and pH stable analogs of the enzyme subtilisin and to a method for generating such analogs. In particular, the present invention relates to analogs of Bacillus subtilisin having a substitution for Asn 218 and to a method for generating such analogs. The term subtilisin designates a group of extracellular alkaline serine proteases produced by various species of Bacilli. These enzymes are also called Bacillus serine proteases. Bacillus subtilisins or bacterial alkaline proteases. The Bacillus subtilisin molecules are composed of a single polypeptide chain of either 274 residues (for subtilisin type Carlsberg produced by Bacillus licheniformis and for the subtilisin produced by Bacillus subtilis strain DY) or 275 residues (for subtilisin type BPN', produced by Bacillus amyloliquefaciens, and the aprA gene product of Bacillus subtilis) . When comparing amino acid sequences of sub¬ tilisin from different strains of Bacillus the sequence of subtilisin BPN' is used as a standard. For example, based on an alignment of sequences that gives the highest degree of homology between subtilisin Carlsberg and subtilisin BPN', the serine at the active site of the former is referred to as serine 221, even though it is located at position 220 of the amino acid sequence. On the same basis, position 220 of the amino acid sequence of subtilisin Carlsberg may said to "correspond" to position 221 of subtilisin BPN' . See e.g., Nedkov et al., Hoppe-Seyler's Z. Physiol. Che . , 364, 1537-1540 (1983). The X-ray structure of subtilisin BPN' [Wright, et al.. Nature, 221, 235 (1969)] revealed that the geometry of the catalytic site of subtilisin, involving Asp 2 , His° 4 and Set ^ , is almost identical to that of the active site of mammalian serine proteases (e.g., chymotrypsin) involving the residues Asp ° , His 57 , and Ser 195 . However, the overall dissimilarities between Bacillus serine proteases and mammalian serine proteases indicate that these are two unrelated families of proteolytic enzymes. In the family of Bacillus subtilisins complete amino acid sequences are available for four subtilisins: Carlsberg, [Smith, et al., J. Biol. Chem., 243, 2184-2191 (1968)]; BPN' [Markland, et al., J. Biol. Chem., 242, 5198-5211 (1967)]; the aprA gene product [Stahl, et al., J. Bacteriol., 158, 411-418 (1984)]; and DY [Nedkov, et al., supra] . Subtilisin Carlsberg and subtilisin BPN' (sometimes referred to as subtilisin Novo) differ by 84 amino acids and one additional residue in BPN' (subtilisin Carlsberg lacls an amino acid residue corresponding to residue 56 of subtilisin BPN'). Smith, et al., supra. Subtilisin DY is 274 amino acids in length and differs from subtilisin Carlsberg in 32 amino acid positions and from subtilisin BPN' by 82 amino acid replacements and one deletion (subtilisin DY lacks an amino acid residue corresponding to residue 56 of subtilisin BPN'). Nedkov, et al., supra. The amino acid sequence of the aprA gene product is 85% homologous to the amino acid sequence of subtilisin BPN'. Stahl, et al., supra. Thus, it seems that there is an extensive homology between amino acid sequences of serine proteases from different strains of Bacillus. This homology is complete in certain regions of the molecule and especially in those that play a role in the catalytic mechanism and in substrate binding. Examples of such sequence invariances are the primary and secondary substrate binding sites, Ser 125 -Leu 12 °- Gly-1-27__QT_--128 anc l <jy r 104 respectively and the sequence around the reactive serine (221) Asn 218 -Gly 19 -Thr 220 - Ser 221 -Met 222 -Ala 223 . Subtilisin molecules exhibit some unique stability properties. They are not completely stable at any pH value although they are relatively resistant to denaturation by urea and guanidine solutions and enzymatic activity is retained for some time even in a solution of 8 M urea. In solutions at a pH below 4, subtilisin rapidly and irreversibly loses its proteolytic activity. Gounaris, et al., Compt. Rend. Trav. Lab. Carlsberg, 35, 37 (1965) demonstrated that the acid deactivation of subtilisin is not due to a general charge effect and speculated that it is due to other changes in the molecule, such as protonation of histidine residues in the interior, hydrophobic parts of the molecule. In solution at pH above 5, Bacillus serine proteases gradually undergo irreversible inactivation at a rate that increases with temperature and pH. The mechanisms of this inactivation are not fully known but there is evidence indicating that autodigestion is responsible at least in part for enzyme instability at this pH range. The use of proteases in industrial processes which require hydrolysis of proteins has been limited due to enzyme instability under operational conditions. Thus, for example, the incorporation of trypsin into laundry detergents (e.g., Bio-38, Schnyder; Switzerland) to facilitate removal of proteinaceous stains had a very limited success which was undoubtedly a result of enzyme instability under the washing conditions. It was only about 1960, after the introduction of the use of bacterial alkaline proteases which are more compatible with detergents that proteases came to be widely used in the detergent industry. For practical reasons many industrial processes are conducted at temperatures that are above the stability range of most enzymes. Therefore, it is reasonable to assume that highly thermostable proteases not only will be advantageous to certain industries such as detergent and hide dehairing, that already require stable proteases, but may be useful in industries that use chemical means to hydrolyze proteins e.g. hydrolysis of vegetable and animal proteins for the production of soup concentrates. It should be pointed out, however, that although thermal inactivation may be the most important mode of enzyme inactivation, factors other than heat such as extremes of pH, oxygen and denaturing agents may have a deter inantal effect on limiting the use of proteases in industrial processes. It is therefore, desirable to obtain proteases that are characterized by improved stability under the operational conditions used in various industries. Such a goal may be accomplished either through searching for new more stable wild-type enzymes or through stabilization of already known existing proteases. Even though the Bacillus-derived alkaline proteases are more compatible with detergent formula¬ tions than were the pancreatic proteases, they are still not ideal in all respects. Over the past several years there have been major changes in detergent formulations, particularly in the replacement of phosphates with alternate builders and in the development of liquid laundry detergents to meet environmental and consumer demands. These changes create a need for changes in traditional detergent enzymes. More particularly, it has become desirable to employ proteolytic enzymes which possess greater storage stability in liquid laundry formulations as well as stability and activity at broader ranges of pH and temperature. In one approach to producing modified sub¬ tilisins for use in detergent formulations, as disclosed in European Patent Application No. 130,756, mutations in the subtilisin of Bacillus amyloliquefaciens (B. amyloliquefaciens) at Tyr "1 , Asp 32 , Asn 155 , Tyr 104 , Met 222 , Gly 166 , His 64 , Gly 169 , Phe 189 , Ser 33 , Ser 221 , Tyr 217 , Glu 156 , and/or Ala 152 are identified as providing changed stability, altered conformation or as having changes in the "processing" of the enzyme. In this context, mutation of Met 222 to Ala, Cys (which mutant also exhibits a sharper pH optimum than wild type) or Ser assertedly results in improved oxidation stability. Substitution for Gly^°° with Ala, Asp, Glu, Phe, Hys, Lys, Asn, Arg or Val appears to alter the kinetic parameters of the enzyme. However, none of the mutations are disclosed to provide analogs having greater stability at high temperatures or stability over a broader pH range than the wild type enzyme. In another approach, it appears that the pH dependence of subtilisin may be altered, as disclosed in Thomas, et al. Nature, 318, 375-376 (1985), by changing an Asp to Ser in Asp 99 -Gly 100 of subtilisin BPN'. This change represents an alteration of a surface charge 14- 15 Angstroms from the active site. However, the approach of Thomas, et al. does not provide an indication of improvement where no change in surface charge is made, as is the case where one uncharged residue is substituted for another. Summary of the Invention The present invention provides analogs of Bacillus serine protease products characterized by improved pH and heat stabilities, rendering them especially useful in detergent formulations as well as other processes requiring protease usage. The present invention also provides an industrially feasible recombinant process for preparing the products free of other proteases. Stable analogs according to the present invention are generally characterized by deletion and/or modification and/or replacement of either residue of Asn-Gly sequences present in the protease. It should be noted that, as employed herein, the term "subtilisin" is used to refer to the mature, secreted form of the enzyme which lacks leader sequences cleaved from the mature enzyme prior to or at secretion. Presently preferred analogs of a Bacillus subtilisin according to the present invention have an amino acid sequence wherein positions comprising an Asn- Gly sequence in the Bacillus subtilisin do not comprise an Asn-Gly sequence in the analog, and in particular wherein there are fewer Asn-Gly sequences than in the Bacillus subtilisin. Most preferably, a position corresponding to position 218 in the amino acid sequence as set forth in Table 1, does not comprise an asparaginyl residue, but rather comprises a residue of a different amino acid, preferably an amino acid selected from among serine, valine, threonine, cysteine, gluta ine and isoleucine. To the extent that replacement of asparagine with certain amino acids may give rise to interference with active site conformation, (e.g., due to steric hindrance which may be introduced by the presence of an aromatic amino acid or changes in tertiary structure such as may be introduced by the presence of a proline) substitution with such amino acids would ordinarily be less preferred. Likewise, to the extent that replacement of asparagine with other amino acids may introduce a charged group (e.g., aspartic acid) into the proximity of the active site, such substitution would be less preferred. Illustrative of a presently preferred embodiment of an analog according to the present invention is a [Ser 18 ]-analog of the aprA gene product. Alternative embodiments of analogs within the contemplation of the invention are those wherein Asn 10 of subtilisin BPN' or of aprA gene product is replaced, preferably by a serine, and wherein glycine residues at positions 110 and/or 219 are replaced by different amino acid residues. In other subtilisins, substitution for Asn at residue 62 or Gly at residue 63 of subtilisins Carlsberg or DY are also comprehended by the present invention. A nucleic acid according to the present inven¬ tion has codons encoding a polypeptide analog as described above. A system for the production of subtilisin according to the present invention comprises a host cell in turn comprising nucleic acid encoding an analog of subtilisin as described above. In such a cell, the nucleic acid encoding the subtilisin analog may be chromosomal or extrachromosomal. The host cell is pref¬ erably selected from a strain deficient in secreted proteases, allowing for facile isolation of analog com¬ pounds. A detergent formulation according to the present invention includes an analog of a Bacillus subtilisin having an amino acid sequence comprising an Asn-Gly sequence wherein one or both residues of the Asn-Gly sequence are deleted or are replaced. A method for improving the thermal and pH stability of subtilisins according to the present inven- tion comprises the step of substituting an amino acid other than asparagine for an asparagine in an Asn-Gly sequence and in particular for the asparagine residue at the position in the amino acid sequence of the subtilisin which corresponds to position 218 in the amino acid sequence as disclosed in Table 1. Brief Description of the Drawings Fig. 1 schematically depicts the cyclization of Asn-Gly residues, such as those found at positions 218 and 219 of subtilisin as set forth in Table 1, to form anhydroaspartylglycine and also depicts base- catalyzed hydrolysis thereof; Fig. 2 is a partial restriction map of an aprA gene-containing an EcoRI-Kpnl gene fragment of Bacillus subtilis (B. subtilis) strain QB127 and includes a partial restriction map of the aprA gene and flanking sequences; Fig. 3 is a partial restriction map of a plasmid pAMBll; Fig. 4 is a flowchart depicting stages in construction of pAMB113, a plasmid which directs synthesis of [Ser] 21 -subtilisin from B_-_ subtilis host cells; and Fig. 5 is a partial restriction map of pAMB30 plasmid. Detailed Description Bacillus serine proteases undergo irreversible inactivation in aqueous solutions at a rate that is largely dependent upon temperature and pH. At pH values below 4 or above 11 the rate of inactivation is very rapid while at pH's of between 4.5 and 10.5 the rate, although much slower, increases as the solution becomes more alkaline. In general, at any pH value, the higher the temperature the faster the rate of subtilisin deac- tivation. A conserved sequence, Asn-Gly, at positions 109-110 and especially at positions 218-219 of Bacillus subtilisins is identified herein as a major factor res¬ ponsible for the pH instability of these substances. The sequence Asn-Gly in proteins and peptides readily undergoes cyclization under various conditions, to form the cyclic imide anhydroaspartylglycine [Bornstein, et al.. Methods in Enzy ol., 47, 132-145 (1977)], as illustrated in Fig. 1. This cyclic imide is susceptible to base-catalyzed hydrolysis which preferentially produces a non-native, s-aspartyl peptide bond. Furthermore, the cyclic imide derived from Asn-Gly may serve as a target for specific cleavage of subtilisin. In fact, the specific cleavage of proteins at Asn-Gly bonds with alkaline hydroxylamine has become a common practice in the preparation of protein fragments for the purpose of amino acid sequencing. [Bornstein, et al., supra] Formation of a cyclic imide and/or β-aspartyl- glycyl peptide at Asn 218 -Gly 219 of subtilisin is pre¬ dicted to cause irreversible inactivation of the enzyme. This prediction is based on the close proximity of the unstable Asn-Gly element to a reactive serine located at position 221. A computer analysis of protein structures led to the belief that rearrangement of Asn 2 ^°-Gly- ^ to either anhydroaspartyl glycyl or to s- aspartyl-glycyl results in a shift of the side-chain of Ser 2 ^ away from the position it must occupy for the enzyme to be active. In order to eliminate the unstable element, Asn 218 -Gly 219 , from the subtilisin molecule one can either replace Asn 218 with any amino acid other than asparagine and/or change Gly 219 to any amino acid other than glycine. In a like manner, modification of the unstable Asn-Gly element at positions 109-110 is expected to provide benefits in the stability of analogs of the invention. The observed invariance of Gly 2 ^ 9 in sub¬ tilisins and in subtilisin-like enzymes [e.g. Cucumisin from the melon Cucumis Melo L. Var Prince, Kaneda, et al., J. Biochem., 95, 825-829 (1984); and proteinase K, a subtilisin-like serine protease from the fungus Tritirachium album, Jany et al., Biol. Chem. Hoppe- • Seyler, 366, 485-492 (1985)] and the assumption that if Gly 219 were any residue other than glycine, its side chain might interfere with binding of a substrate to the enzyme, make highly preferred the change of Asn 2 - 1 - 8 rather than Gly 219 for the removal of the unstable Asn 218 -Gly 219 sequence. Based on theoretical considerations and on the compilation and analysis of sequencing data, asparagine at position 218 was replaced by serine in the presently preferred embodiment of the present invention described in the following illustrative examples. This selection was based in part on the observation that the amino acid sequence around the reactive serine of cucumisin, a subtilisin-like enzyme from melon fruit, has the sequence Ser-Gly-Thr-Ser-Met (Kaneda, et al., supra) . Proteinase K has the same sequence around the active site. Jany et al., supra. It should be emphasized, however, that the selection of serine as a substitute for Asn 218 does not preclude achieving the same goal, i.e., elimination of the unstable element Asn 218 -Gly 219 , through replacing asparagine at position 218 with a different amino acid. It is preferred that an uncharged aliphatic amino acid, such as valine, threonine, cysteine, glutamine or isoleucine be substituted for Asn 218 . Due to their capacity to secrete substantial quantities of proteins and because they are currently used to produce detergent proteases. Bacillus micro¬ organisms represent a preferred host for recombinant production of the [Ser 218 ]-subtilisin according to the present invention. Because most Bacilli secrete alka¬ line and neutral proteases, it is preferable that mutations be introduced into the endogenous alkaline and neutral protease genes of B_-_ subtilis so that the mutated subtilisin may be produced and secreted by B_-_ subtilis in a medium free of other proteases. Thus the present invention also provides mutant strains of B. subtilis which are blocked with respect to the synthesis of endogenous proteases but which retain the ability to synthesize and secrete subtilisin analogs such as [Ser 218 ]-subtilisin. As described in greater detail below, it was found that the pH and thermal stability and the stability in detergent formulations of [Ser 2 ^ ]-a_p_rA gene product subtilisin is much greater than that of the wild type aprA gene product subtilisin. The production of a stable subtilisin analog according to the invention included the following procedures: 1. Isolation of the representative subtilisin gene apr A from B^ subtilis; 2. Cloning of the apr A gene on a vector which permits utilization of oligonucleotide site- directed mutagenesis to create desired modifications; 3. Site-directed mutagenesis and sequencing of the resulting DNA to confirm the presence of the desired mutation; 4. Construction of an expression vector to direct the synthesis of the mutated enzyme in B. subtilis; 5. Construction of mutated B_-_ subtilis strains which do not synthesize subtilisin and neutral protease; 6. Isolation of the enzyme in the extra¬ cellular growth medium and its purification; 7. Assessment of stability and activity characteristics of the isolated product; and 8. Practice of procedures for insertion of the gene coding for the improved enzyme into the chromosome of a B^ subtilis strain previously mutated to block synthesis of endogenous proteases. In Example 1, the aprA gene encoding sub¬ tilisin is isolated from the B^ subtilis genome. In Example 2, the aprA gene is subjected to site-directed mutagenesis. In Example 3, an expression vector con¬ taining the mutated aprA gene is constructed. In Example 4, two mutant strains of B^ subtilis which produce no detectable extracellular proteases are constructed. Example 5 describes procedures for integration of a mutated aprA gene into the chromosome of B^ subtilis. In Example 6, wild-type and mutant aprA subtilisins are isolated and purified. Examples 7 through 10 compare the thermostability of [Ser 2 ^ 8 ] sub¬ tilisin to that of wild-type aprA gene product and to that of a commercial BPN' product. Example 1 B. subtilis strain QB127 (trpC2 leuA8 sacU h 200) [Lepesant, et al., Molec. Gen. Genet., 118, 135-160 (1982)] was obtained from the Bacillus Genetic Stock Center at the Ohio State University, Columbus, Ohio. This strain overproduces extracellular serine and metal proteases, α-amylase and levansucrase relative to isogenic s_acU + strains due to the pleiotropic effect of the sacU"200 mutation [Lepesant, et al., m Schlessinger, D., ed. , Microbiology, 1976, American Society for Microbiology, Washington, D.C., p. 65 (1976)] Strain QB127 was thus perceived to be a suit¬ able source of DNA for isolating the aprA gene which codes for subtilisin. Genomic DNA was isolated from cells of B_-_ subtilis strain QB127 by a published procedure [Saito, et al., Biochim. Biophys. Acta. 72, 619-629 (1963)]. Purified chromosomal DNA was digested to completion with the EcoRI restriction endonuclease. DNA fragments were resolved on a low-melting point agarose gel by electrophoresis and fragments in the 4.4 to 8.0 kilobase (kb) range were isolated by a standard DNA isolation procedure as recommended by the supplier (Bethesda Research Laboratories, Inc., Gaithersburg, Maryland) . These fragments were ligated to pCFM936 deposited as No. 53,413 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, on January 13, 1986, an Ξscherichia coli (E. coli) "walkaway" plasmid which displays higher copy numbers at elevated temperatures and which confers kanamycin resistance. The vector was digested with EcoRI and dephos- phorylated with calf intestine alkaline phosphatase prior to ligation. Ligation products were introduced into E_ ; _ coli C600 (available as A.T.C.C. 23724 from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland) and kanamycin-resistant host cells were selected after overnight incubation on L-agar supple¬ mented with 10 μg/ml kanamycin. Plasmid DNA was ampli- fied by incubating host cells at 42°C for 4 hours. Colonies were then transferred to nitrocellulose filters and processed by a published procedure referred to as colony hybridization [Grunstein, et al., Proc. Natl. Acad. Sci. (USA), 12. , 3961 (1975)]. A probe was used to screen for colonies which harbored the subtilisin gene on pCFM936. The probe [synthesized by the phosphite chemistry method of Beaucage, et al.. Tetrahedron Letters, 22, 1859-1862 (1981)] had the nucleotide sequence (1) 5' GCGCAATCTGTTCCTTATGGC 3* which corresponds to the amino-ter inus of the aprA gene product (Wong, et al., Proc. Natl. Acad. Sci. (USA), 81, 1184-1188 (1984); Stahl, et al., J. Bacteriol., 158, 411-418 (1984). A hybridization temperature of 55°C was used and 5 positive colonies were identified out of a total of 400. The plasmid DNA from one of the positive colonies was designated pCFM936 apr2. Plasmid pCFM936 apr2 was digested with EcoRI alone with Hindlll alone and with EcoRI and Hindlll in combination. Sizes of EcoRI fragments of the subtilisin gene conformed to those described in Stahl, et al., supra, but several otherwise undescribed Hindlll sites were discovered. As described in Example 3, two of the Hindlll sites were employed for genetic manipulations of the subtilisin gene. It was determined that a large 6.5 kb EcoRI fragment of B^ subtilis QB127 genomic DNA carried the aprA gene, its regulatory sequences and unrelated flanking sequences by verifying that restriction enzyme digests conformed to the results reported by Stahl, et al., supra. This was confirmed by DNA sequencing using the dideoxy chain termination method [Sanger, et al., J. Mol. Biol., 143, 161-178 (1980)]. A 3.0 kb EcoRI to Kpnl subfragment of the 6.5 kb EcoRI fragment, as illustrated in Fig. 2, was also found to contain the aprA gene, its regulatory sequences, and unrelated flanking sequences. Although the KpnI-EcoRI fragment is reported to be 2.5 kb in length in the text of Stahl, et al., and in the legend to Fig. 1 therein, comparison of the scale of Fig. 1 and the scaled depiction of the fragment therein reveal that, even in Stahl, et al., the KpnI-EcoRI fragment is substantially larger than 2.5 kb. A cloning vector for Bacillus host systems, plasmid pAMBll, was constructed as follows. The plasmid pTG402 (Northern Regional Research Laboratories, United States Department of Agriculture, Peoria, Illinois, strain number NRRL B-15264) was partially digested with the Rsal restriction endonuclease. Fragments were ligated to M13 mp_18 (available from Bethesda Research Laboratories, Gaithersburg, Maryland as catalog number 8227SA) which had been previously digested with Hindi. Ligation products were introduced into E_ ; _ coli JM103 (available from Pharmacia, Inc., Piscataway, New Jersey as catalog number 27-1545-01) by transformation [Mandel, et al., J. Mol. Biol., 5_3, 154, (1970)]. Bacteriophage plaques were sprayed with 0.5M catechol (prepared in distilled water) to detect the functional expression of the xylE gene derived from pTG402. The xylE gene encodes catechol 2,3-dioxygenase and is useful for detecting promoters in a variety of organisms. Zukowski, et al., Proc. Natl. Acad. Sci. (USA), 80, 1101-1105 (1983). The xylE gene was then transferred as a 1.0 kb EcoRI to PstI fragment to the E_-_ coli/B. subtilis plas¬ mid pHV33 (available from the American Type Culture Collection as A.T.C.C. 39217) [Primrose, et al. Plasmid, 6_, 193-201 (1981)] obtained from R. Dedonder (Institut Pasteur, Paris, France). The pHV33 plasmid had been previously digested with EcoRI and PstI so that the xyIE-containing fragment, when ligated in this region, would inactivate a gene for ampicillin resistance. The resulting plasmid, pAMB21, contains a functional xylE gene in E^ coli host cells, but requires the addition of a promoter for xylE to be expressed in B. subtilis host cells. E^ coli cells harboring pAMB21 are resistant to tetracycline (15 μg/ml) and chloramphenicol (20 μg/ml) while B_^ subtilis cells harboring pAMB21 are resistant only to chloramphenicol (5 μg/ml). The toop transcription termination sequence of bacteriophage lambda was then transferred from plasmid pCFM936 (on a 400 base pair PstI to Bglll fragment) to the unique PstI site of pAMB21. A synthetic nucleotide with the sequence 5' GATCTGCA 3' was constructed to join the Bglll extremity of the toop fragment to the PstI site of the vector pAMB21. The resulting plasmid was designated pAMB22 and had properties indentical to pAMB21 except for the inclusion of a transcription ter- minator. The pAMB22 plasmid is useful for detecting strong promoters that are functional in B_-_ subtilis. The 1.4 kb EcoRI to Bglll fragment of DNA from pAMB22 that contains xylE and toop was isolated from a low-melting point agarose gel after electrophoresis of restricted fragments. The 1.4 kb piece of DNA was ligated to plasmid pBD64 (available from Bacillus Genetic Stock Center, number 1E22) which had been previously digested with EcoRI and BamHI. The resulting 5.3 kb plasmid, pAMBll, contains the polylinker sequence of Ml3mpl8 (EcoRI, SstI, Xmal, Sma, BamHI and Xbal) upstream of the xylE gene which is followed by toop, as shown in Figure 3. The pAMBll plasmid is capable of replicating in B_-_ subtilis and confers upon host cells resistance to chloramphenicol (5 μg/ml) and/or kanamycin As illustrated in Fig. 4, the purified EcoRI to Kpnl fragment containing aprA was cloned onto pAMBll to form pAMBlll. Ligation products were introduced into B. subtilis MI112 (arg-15 leuB thr5 recE4) (available from Bacillus Genetic Stock Center as No. 1A423) by the protoplast transformation method [Chang, et al., Mol. Gen. Genet., 168, 111-115 (1979)]. B. subtilis MI112 without plasmid DNA is protease-proficient (Prt + phenotype), but secreted levels of subtilisin are rather low. Chloramphenicol-resistant (Cm r ) transformants were transferred onto L-agar plates supplemented with 1.5% (w/v) skim milk and 5 μg/ml chloramphenicol, then incubated at 37°C. After overnight (approx. 16 hrs.) incubation at 37°C, colonies of MI112 harboring the new recombinant plasmid (designated pAMBlll) produced a clear halo surrounding each colony. Halos were formed by the pro- teolytic action of subtilisin on the casein component of the skim milk medium supplement. MI112 harboring the pAMBll vector alone had no visible halo after 16 hrs., although a slight halo eventually developed after 40 hrs. at 37°C. Cells carrying pAMBlll were clearly dis¬ tinguished from cells carrying pAMBll by a difference in halo size. The cloning of the aprA gene in a fully functional form was thus demonstrated to have led to the high level production and secretion of subtilisin by B. subtilis. Example 2 As further illustrated in Fig. 4, the 3.0 kb EcoRI to Kpnl genomic fragment, the isolation of which is described in Example 1, was digested with Hindlll to produce three fragments: (1) a 1.1 kb EcoRI to Hindlll fragment carrying genetic regulatory sequences for aprA gene expression, the "pre-pro" region of the gene required to extracellular export of subtilisin, and the DNA sequence coding for the first 49 amino acids of mature subtilisin; (2) a 1.1 kb Hindlll to Hindlll frag¬ ment carrying DNA sequences coding for amino acids 50 through 275 (carboxyl-terminus) of subtilisin along with a transcription termination sequence and 3' non-coding sequences; and (3) a 0.8 kb Hindlll to Kpnl fragment containing 3' non-coding sequences. The 1.1 kb fragment flanked by Hindlll sites was cloned to the single Hindlll site of bacteriophage M13 mp!8 for the purposes of DNA sequencing and site- directed mutagenesis. One of the recombinants, desig¬ nated M13 mpl8 apr2, provided single stranded template DNA required for site-directed mutagenesis of the aprA gene. The coding region of the aprA gene was sequenced and the results of the sequence are set out in Table 1 below. It should be noted that the specific identity of the initial 5 codons of the leader region is attributable to the report of Stahl, et al., supra, and Wong, et al., supra, of sequence information for the aprA gene, and that there exist codon sequence differences from Stahl, et al., supra, at amino acid positions 84 and 85 which may be the result of sequencing error on the part of the authors of the Stahl, et al. reference or which may be the result of a difference in the nucleotide sequences of the strains employed. Specifically, Stahl, et al., supra, reports a codon GTT (coding for valine) at amino acid position 84 while the codon GTA (also coding for valine) appears in Table 1. Stahl, et al., supra, also reports a codon AGC (coding for serine) at amino acid position 85 as opposed to the codon GCG (coding for alanine) in Table 1. TABLE 1 -105 fMet Arg Ser Lys Lys Leu Trp lie Ser Leu Leu Phe Ala GTG AGA AGC AAA AAA TTG TGG ATC AGC TTG TTG TTT GCG Leu Thr Leu lie Phe Thr Met Ala Phe Ser Asn Met Ser Ala TTA ACG TTA ATC TTT ACG ATG GCG TTC AGC AAC ATG TCT GCG Gin Ala Ala Gly Lys Ser Ser Thr Glu Lys Lys Tyr lie Val CAG GCT GCC GGA AAA AGC AGT ACA GAA AAG AAA TAC ATT GTC Gly Phe Lys Gin Thr Met Ser Ala Met Ser Ser Ala Lys Lys GGA TTT AAA CAG ACA ATG AGT GCC ATG AGT TCC GCC AAG AAA Lys Asp Val lie Ser Glu Lys Gly Gly Lys Val Gin Lys Gin AAG GAT GTT ATT TCT GAA AAA GGC GGA AAG GTT CAA AAG CAA Phe Lys Tyr Val Asn Ala Ala Ala Ala Thr Leu Asp Glu Lys TTT AAG TAT GTT AAC GCG GCC GCA GCA ACA TTG GAT GAA AAA Ala Val Lys Glu Leu Lys Lys Asp Pro Ser Val Ala Tyr Val GCT GTA AAA GAA TTG AAA AAA GAT CCG AGC GTT GCA TAT GTG -1 +1 Glu Glu Asp His lie Ala His Glu Tyr Ala Gin Ser Val Pro GAA GAA GAT CAT ATT GCA CAT GAA TAT GCG CAA TCT GTT CCT 10 Tyr Gly lie Ser Gin lie Lys Ala Pro Ala Leu His Ser Gin TAT GGC ATT TCT CAA ATT AAA GCG CCG GCT CTT CAC TCT CAA 20 30 Gly Tyr Thr Gly Ser Asn Val Lys Val Ala Val lie Asp Ser GGC TAC ACA GGC TCT AAC GTA AAA GTA GCT GTT ATC GAC AGC 40 Gly lie Asp Ser Ser His Pro Asp Leu Asn Val Arg Gly Gly GGA ATT GAC TCT TCT CAT CCT GAC TTA AAC GTC AGA GGC GGA 50 60 Ala Ser Phe Val Pro Ser Glu Thr Asn Pro Tyr Gin Asp Gly GCA AGC TTC GTA CCT TCT GAA ACA AAC CCA TAC CAG GAC GGC 70 Ser Ser His Gly Thr His Val Ala Gly Thr He Ala Ala Leu AGT TCT CAC GGT ACG CAT GTA GCC GGT ACG ATT GCC GCT CTT TABLE 1 (cont'd. ) 80 Asn Asn Ser He Gly Val Leu Gly Val Ala Pro Ser Ala Ser AAT AAC TCA ATC GGT GTT CTG GGC GTA GCG CCA AGC GCA TCA 90 100 Leu Tyr Ala Val Lys Val Leu Asp Ser Thr Gly Ser Gly Gin TTA TAT GCA GTA AAA GTG CTT GAT TCA ACA GGA AGC GGC CAA 110 Tyr Ser Trp He He Asn Gly He Glu Trp Ala He Ser Asn TAT AGC TGG ATT ATT AAC GGC ATT GAG TGG GCC ATT TCC AAC 120 130 Asn Met Asp Val He Asn Met Ser Leu Gly Gly Pro Thr Gly AAT ATG GAT GTT ATC AAC ATG AGC CTT GGC GGA CCT ACT GGT 140 Ser Thr Ala Leu Lys Thr Val Val Asp Lys Ala Val Ser Ser TCT ACA GCG CTG AAA ACA GTC GTT GAC AAA GCC GTT TCC AGC 150 Gly He Val Val Ala Ala Ala Ala Gly Asn Glu Gly Ser Ser GGT ATC GTC GTT GCT GCC GCA GCC GGA AAC GAA GGT TCA TCC 160 170 Gly Ser Thr Ser Thr Val Gly Tyr Pro Ala Lys Tyr Pro Ser GGA AGC ACA AGC ACA GTC GGC TAC CCT GCA AAA TAT CCT TCT 180 Thr He Ala Val Gly Ala Val Asn Ser Ser Asn Gin Arg Ala ACT ATT GCA GTA GGT GCG GTA AAC AGC AGC AAC CAA AGA GCT 190 200 Ser Phe Ser Ser Ala Gly Ser Glu Leu Asp Val Met Ala Pro TCA TTC TCC AGC GCA GGT TCT GAG CTT GAT GTG ATG GCT CCT 210 Gly Val Ser He Gin Ser Thr Leu Pro Gly Gly Thr Tyr Gly GGC GTG TCC ATC CAA AGC ACA CTT CCT GGA GGC ACT TAC GGC 220 Ala Tyr Asn Gly Thr Ser Met Ala Thr Pro His Val Ala Gly GCT TAT AAC GGA ACG TCC ATG GCG ACT CCT CAC GTT GCC GGA 230 240 Ala Ala Ala Leu He Leu Ser Lys His Pro Thr Trp Thr Asn GCA GCA GCG TTA ATT CTT TCT AAG CAC CCG ACT TGG ACA AAC 250 Ala Gin Val Arg Asp Arg Leu Glu Ser Thr Ala Thr Tyr Leu GCG CAA GTC CGT GAT CGT TTA GAA AGC ACT GCA ACA TAT CTT TABLE 1 (cont'd. ) 260 270 Gly Asn Ser Phe Tyr Tyr Gly Lys Gly Leu He Asn Val Gin GGA AAC TCT TTC TAC TAT GGA AAA GGG TTA ATC AAC GTA CAA 275 Ala Ala Ala Gin OC GCA GCT GCA CAA TAA TAGTAAAAAGAAGCAGGTTCCTCCATACCTGCT TCTTTTTATTTGTCAGCATCCTGATGTTCCGGCGCATTCTC Site-directed mutagenesis was performed by a standard method. Norrander, et al.. Gene, 26, 101-106 (1983). Single-stranded DNA from M13 mp!8 apr2 was annealed to the mutagenic primer (2) 5' GGCGCTTATAGCGGAAC 3' which was synthesized by the phosphite chemistry method (Beaucage, et al., supra) . The synthetic primer was homologous to codons for amino acids 216 through 220 of subtilisin with the exception of a single base change in the codon for amino acid 218 (AGC instead of AAC) . Such a change allowed the mutagenic reaction to substitute a serine codon at position 218 in place of the original asparagine codon at this position. The synthetic primer was annealed to M13 mp!8 apr2 DNA at 65°C before being slowly cooled to room temperature (approx. 22°C). Polymerization followed for 2 hr. at 15°C in a reaction mixture which consisted of 12.5 μl of annealed DNA solution, 2.5 μl of 10 mM each dATP, dGTP, dCTP and dGTP, 2.0 μl of 12 mM ATP, 0.1 μl Klenow DNA polymerase, 0.1 μl T4 DNA ligase and 13 μl sterile distilled water. The resulting double-stranded, covalently closed circular DNA was introduced into E. coli JM103 by transfection. Bacteriophage plaques were then transferred to Gene Screen™ (New England Nuclear, Beverley, Massachusetts) hybridization membranes. Plaques which contained DNA with the desired base change were identi¬ fied by hybridization to radioactively labeled (γ- 32 P) synthetic oligonucleotide (2) used for the mutagenic priming reaction described above. Hybridization was performed at a restrictive temperature (52°C) so that only DNA carrying the Ser 218 mutation would hybridize to the synthetic oligonucleotide. The presence of the Ser -64-0 mutation in the aprA gene on DNA from a single purified plaque, designated M13 mp!8 apr2 [Ser] 218 , was confirmed by DNA sequencing by the method of Sanger, et al., supra. Example 3 In order to express [Ser 21 ]-subtilisin in B. subtilis, a suitable plasmid vehicle was constructed by digesting pAMBlll with Hindlll. The 1.1 kb segment carrying most of the aprA gene was deleted by re¬ ligating Hindlll digestion products of pAMBlll at a concentration of approximately lμg/ml. This resulted in the formation of pAMBllO as illustrated in Fig. 4. The pAMBllO plasmid carries genetic regulatory sequences for expression of the subtilisin gene, the "pre-pro" region required for secretion of subtilisin, and the DNA sequence coding for the 3' non-coding region of mature subtilisin and the first 49 amino acids of mature subtilisin. Because it is lacking DNA coding for amino acids 50 through 275, pAMBllO does not synthesize sub- tilisin when introduced into B subtilis host cells. Subtilisin is synthesized only after insertion of the remainder of a subtilisin gene, either the native DNA sequence or an analog-encoding sequence, such as a sequence encoding [Ser 2 -'- 8 ]-subtilisin. Double-stranded DNA from M13 mplδ apr2 [Ser] 218 was digested with Hindlll. A 1.1 kb fragment carrying the aprA gene segment with the Ser 218 mutation was then ligated to pAMBllO which had been previously digested with Hindlll. Ligation products were intro- duced into B_-_ subtilis by transformation as in Example 1 above. Ligation of the 1.1 kb Hindlll fragment in the correct orientation (as confirmed by DNA sequencing by the method of Sanger, et al. supra) for expression of the mutated gene resulted in the construction of pAMB113, a plasmid which directed synthesis and secre¬ tion of [Ser 218 ]-subtilisin from EL_ subtilis host cells. Example 4 Because most Bacilli secrete alkaline and/or neutral proteases into the surrounding growth medium, it is preferable that mutations be introduced into endog¬ enous alkaline and neutral protease genes of B^ subtilis to block their synthesis so that mutated subtilisin genes, when introduced into the mutant cell, may produce mutated subtilisins which will then be secreted in a medium free of other proteases likely to interfere with isolation of intact subtilisin analogs. Two mutant B. subtilis strains BZ24 and BZ25, which produce no detectable extracellular proteases, were constructed in the following manner. First, a plasmid vehicle capable of replicat¬ ing in E_-_ coli, but not in B^ subtilis unless integrated into the B^ subtilis chromosome by homologous recombina¬ tion, was constructed as follows. Plasmid pBD64 (Bacillus Genetic Stock Center, Number 1E22) was digested to completion with Hpall to produce three frag¬ ments of 2.95 kb, 1.0 kb and 0.75 kb in size. These fragments were then ligated as a mixture to plasmid pBR322 (A.T.C.C. 37017) which previously had been digested with Clal. Ligation products were introduced into E_-_ coli C600 (available from the American Type Culture Collection as A.T.C.C. 23724) by transformation [Mandel, et al., J. Mol. Biol., 5_3, 154 (1970)]. Selec¬ tion was for cells resistant to chloramphenicol (20 μg/ml) and ampicillin (50 μg/ml). Plasmid DNA from 12 transformants was prepared by an alkaline extraction procedure [Birnboim, et al.. Nucleic Acids Res., 1_, 1513-1523 (1979), then digested with Hindlll and EcoRI in combination to verify the presence of inserted frag¬ ments). One such plasmid, designated pAMB30, was found to carry the 1.0 and 0.75 kb Hpall fragments of pBD64 in the Clal site of pBR322. These fragments contain the chloramphenicol acetyltransferase (cat) gene which is functional in E^_ coli and B_^ subtilis. Digestions with Bglll and, separately, with Sau3A confirmed the identity and orientation of the cat gene on pAMB30, as illustrated in Fig. 5. Because pAMB30 lacks an origin of replication sequence which is functional in B^ subtilis, it cannot replicate as an autonomous replicon in B^ subtilis host cells. On the other hand, pAMB30 contains the pBR322- derived origin of replication which is functional in ' E. coli. thus the plasmid can be propagated in E^ coli host cells. Plasmid pAMB30 is useful in at least 2 ways. First, a fragment of DNA which contains a functional origin of replication in B_-_ subtilis may be detected when cloned onto pAMB30 such that the plasmid will autonomously replicate in the extrachromosomal state. Second, plasmid pAMB30 can integrate into the genome of ____ subtilis at a site of homology between the chromosome and B^ subtilis DNA cloned onto pAMB30. Such an event has been repeatedly demonstrated in the past [Haldenwang, et al., J. Bacteriol., 142, 90-98 (1980); Young, J. Gen. Microbiol., 129, 1497-1512 (1983)] by using plasmid vehicles similar to, but not identical with, pAMB30. Plasmid pAMB21 (described in Example 1) was digested with EcoRI and PstI to isolate the xylE gene on a 1.0 kb fragment. The fragment was ligated to pAMB30 which had been previously digested with EcoRI and PstI. Ligation products were introduced into E_ j _ coli C600 by transformation. Selection was for chlor¬ amphenicol resistant (20 μg/ml) host cells which were sensitive to ampicillin (50 μg/ml) due to the insertion of the xylE fragment of pAMB21 into the structural gene for ampicillin resistance of pAMB30. The resulting plasmid, pAMB30/21, has properties identical to pAMB30 but has, in addition, a functional xylE gene. Plasmid pAMBllO, which carries the aprA gene deleted of a region coding for the latter 226 amino acids of mature subtilisin, was digested with EcoRI and Kpnl. The 1.9 kb fragment of B_-_ subtilis DNA containing genetic regulatory sequences for aprA gene expression, "the pre-pro" region, the DNA sequence coding for the first 49 amino acids of mature subtilisin and 3.' non- coding sequences was ligated to pAMB30/21 that had been previously digested with EcoRI and Kpnl. Ligation products were introduced into E_^_ coli C600 by transformation. Plasmid DNA from several transformants was isolated by the alkaline extraction procedure of Birnboim, et al., supra, and the presence of the inserted 1.9 kb fragment was verified by multiple restriction endonuclease digestions. One such plasmid, designated pAMB301, was retained for further use. B. subtilis strain BGSC1A274 (Bacillus Genetic Stock Center) carries a mutation at the npr locus and is incapable of producing extracellular neutral protease. The plasmid pAMB301 was integrated into the genome of B. subtilis BGSC1A274 by transformation of competent cells [Spizizen, Proc. Natl. Acad. Sci. (USA), 44, 1072-1078 (1958)]. Selection was for chloramphenicol-resistant (5 μg/ml) host cells which were then transferred by sterile toothpicks to L-agar supplemented with 1.5% (w/v) powdered skim milk and (5 μ/ml) cloramphenicol. Those cells which failed to produce a clear halo surrounding the colony were deficient . in the ability to produce extracellular neutral and serine proteases due to the combination of the npr mutation along with the newly introduced aprA mutation. The aprA mutation was a deletion of the latter 226 amino acids of mature subtilisin due to the replacement of the wild-type aprA gene with the deleted version carried on pAMB301. One such strain, designated BZ24, has the Npr " Apr " Cm r phenotype, thus it produces no detectable extracellular neutral protease nor extracellular alkaline protease and is resistant to chloramphenicol at 5 μg/ml. Southern blotting [Southern, J. Mol. Biol., 98_, 503-517 (1975)] was used to confirm the deletion in the aprA gene on the chromosome of B^ subtilis BZ24. Cultivation of B. subtilis BZ24 in Antibiotic Medium No. 3 (Penassay Broth, Difco, Detroit, Michigan) in the absence of antibiotic selection for approximately 32 generations led to the isolation of a derivative strain of BZ24 in which the cat gene confering chloramphenicol resistance upon host cells was lost due to its instability in the BZ24 chromosome. Such a phenomenon has been previously observed in similar experiments [Stahl, et al., J. Bacteriol. , 158, 411-418 (1984)]. A chloramphenicol- sensitive derivative of BZ24 was designated BZ25. B. subtilis BZ25 has the Npr " Apr " phenotype, thus it produces no detectable extracellular neutral protease nor extracellular alkaline protease. Southern blotting was used to confirm the deletion in the aprA gene on the chromosome of B_-_ subtilis BZ25. Because B^ subtilis BZ25 produces no detectable extracellular neutral protease nor subtilisin, it is a useful host strain for introduction of plasmid DNA, such as pAMB113, for the production of mutated subtilisins which may be secreted into the surrounding growth medium free of other proteases. B. subtilis BZ25 produces no detectable extra¬ cellular proteases when culture supernatants are assayed as described below. B_-_ subtilis BZ25/pAMBH3, which is BZ25 that harbors plasmid pAMB113 (introduced by the protoplast transformation method of Chang, et al., supra) produces appreciable quantities of [Ser 218 ]- subtilisin when culture supernatants are assayed as described. Example 5 Integration of the [Ser 218 ]-subtilisin gene into the chromosome of B^ subtilis was believed to provide an efficient way of increasing genetic stability of this mutant gene. Such an approach also alleviates the requirement for chloramphenicol in the fermentation medium which is otherwise needed for application of selective pressure to maintain plasmid DNA in the extra- chromosomal state. Therefore, the [Ser 218 ]-subtilisin gene, along with its genetic regulatory sequences and flanking DNA homologous to the B^ subtilis chromosome, was isolated from a low melting point agarose gel after electrophoresis of pAMB113 which had been digested with EcoRI and PstI in combination. The 4.0 kb EcoRI to PstI fragment (illustrated in Fig. 4) was then ligated to pAMB30 (illustrated in Fig. 5) which had been digested with EcoRI and PstI in combination. Ligation products were introduced into Ξ_-_ coli HB101 (A.T.C.C. 33694) by transformation. Selection was for cells resistant to chloramphenicol (20 μg/ml). Plasmid DNA from four transformants which met the criteria above were isolated by the alkaline extraction procedure of Birnboim, et al., supra, then digested with EcoRI and PstI in combination. All four plasmids contained the 4.0 kb insert and the 5.6 kb remaining portion of pAMB30. One such plasmid, designated pAMB302, was purified and retained for further use. Repeated attempts to integrate plasmid pAMB302 into the chromosome of B^ subtilis BZ25 by the competence method [Spizizen, supra] were unsuccessful. This may have been due to the failure of BZ25 cells to become competent by the method employed. Therefore, pAMB302 was introduced into B_-_ subtilis BZ25 cells by the protoplast transformation method of .Chang, et al., supra. This is believed to be the first demonstration that the protoplast transformation method is successful for obtaining integration of heterologous DNA in Bacillus. This result is particularly significant in that research strains in which integration has been obtained were selected on the basis of transformation by the competence method. Strains which may be unable to become competent, and in particular industrial strains which were not selected on the basis of transformation by the competence method, may be more likely to be unable to become competent. Selection was for chloramphenicol-resistant cells (5 μg/ml) cells, which were then transferred with sterile toothpicks to L-agar supplemented with 1.5% (w/v) skim milk and 5 μg/ml chloramphenicol. Cells were incubated overnight at 37°C. Clear halos of different diameters were observed around the Cm r colonies. This indicates that subtilisin was produced and secreted by these cells. An attempt was made to isolate plasmid DNA from eight of these colonies by the alkaline extraction method. No plasmid DNA was detected on agarose gels which were stained with ethidium bromide (1 μg/ml) to visualize DNA after electrophoresis. The absence of extrachromosomal plasmid DNA in the Cm r cells which produced subtilisin was a strong indication that pAMB302 had been integrated into the chromosome of B. subtilis. Several colonies resulting from this experiment were isolated and designated BZ28, BZ29, BZ30, BZ31, BZ32 and BZ33. Each strain was grown overnight at 37°C with vigorous shaking in brain heart infusion medium (BHI, Difco) supplemented with 5 μg/ml chloramphenicol. Culture supernatants were assayed for subtilisin activity. B^ subtilis strains BZ28, BZ29, BZ30, BZ31, BZ32 and BZ33 all produced subtilisin and secreted it into the surrounding growth medium, some strains producing more than others. The amount of sub- tilisin observed in the liquid culture broth was directly proportional to the size of the halo observed on skim milk L-agar plates. Because of the amounts of subtilisin secreted by these cells differed, it was postulated that either multiple copies of pAMB302 were integrated into the chromosome or that gene amplifica¬ tion [Young, J. Gen. Microbiol., 129, 1497-1512 (1983); Albertini, et al., J. Bacteriol., 162, 1203-1211 (1985)] had taken place. Example 5 Wild-type subtilisin, from BZ25/pAMBlll, and [Ser 218 ]-subtilisin, from BZ25/pAMB113, were isolated and purified as follows. Each culture broth was centrifuged at 15,000g for 30 minutes and protein in the clear supernatant was precipitated with (NH^^SO^ (350g per liter) . The precipitate was collected by centrifugation and after trituration with 75% acetone, it was filtered and dried under a vacuum. In order to further purify the enzyme, the dried precipitate was dissolved in. ater and the solu¬ tion was filtered and then dialyzed against 0.02M sodium phosphate buffer at pH 6.3. The dialyzed solution was passed through a column (2.5 x. 15cm) of carboxymethyl cellulose at a rate of 2 ml per minute. After washing the column with 0.02M sodium phosphate (pH 6.3), the enzyme was eluted with the same buffer containing 0.15M NaCl. Peak fractions were pooled and protein from the fractions containing the enzyme, as identified by a color change in a sample of the fraction mixed with succinyl-L-alanyl-L-alanyl-L-prolyl-L-phenylalanyl-p- nitroanilide (Vega Biochemicals) , were precipitated by addition of 2.5 volumes of acetone. The precipitate was collected by centrifugation and then dissolved in 0.005M calcium acetate (about 1 ml per 10 mg). The resulting solution was dialyzed at 4°C against water and then lyophilized. Example 7 Because the present invention relates to the stabilization of Bacillus subtilisin, an analysis of enzyme stability and quantitation thereof was undertaken. Most enzymes express their biological acti- vity, i.e., catalysis of chemical reactions, only within a narrow range of pH and temperature. Moreover, even under optimal conditions, the enzyme will retain its activity only if its polypeptide chain is folded in a manner that forms the so-called native conformation. The native form of an enzyme is therraodynamically more stable than the denatured or unfolded form by an average of 10-15 kilocalories per mole. Unfolding of the native structure often occurs when the enzyme is exposed to extremes of pH or temperature, or to certain concentra- tions of chemicals such as detergents, urea and organic solvents. Removal of these denaturing agents often result in spontaneous refolding of the peptide chain to the native form, and in restoration of the original enzyme activity. Irreversible loss of enzyme activity may occur due to cleavage of the polypeptide chain or due to modification of certain amino acid side chains, especially if these modifications alter the native architecture of the enzymes' active site. Examples of such modifications include the deamidation of asparaginyl and glutaminyl residues, the oxidation of methionyl residues and the hydrolytic cleavage of cysteine to form one residue of thiocysteine and one of dehydroalanine. The present invention provides an additional example in the form of the irreversible inactivation through cyclization of Asn-Gly sequences. When the enzyme preparation includes several enzymatic forms which inactivate at different rates and/or when the inactivation process occur through a number of mechanisms, the kinetics of inactivation are complicated. However, for most enzyme preparations at a suitable range of pH and temperature, the thermal inactivation follow first-order kinetics, i.e., the residual enzyme activity decreases as a function of time along an exponential decay curve. Under these conditions the half-life (T-1 / 2) of the enzyme is independent of the initial enzyme concentration and may be calculated according to: (t 2 -t 1 )ln2 1/2 lnA,-lnA 2 in which -^ and A 2 are the enzyme activities at times t^_ and t2 respectively. In general, everything else being equal, the half-life of an enzyme in solution is shorter at higher temperatures. In order to compare the thermostability of the [Ser 218 ]-aprA gene product subtilisin to that of wild- type aprA gene product subtilisin and subtilisin BPN' (Sigma), solutions of these enzymes (1 mg/ml) were prepared in 0.1M sodium glycinate buffer at pH 10.0. The solutions were incubated at 52°C and after various times aliquots (20 μl) were drawn and mixed with 900 μl of 0.2% casein solution in 0.1M Tris buffer at pH 8.30. As a control, the substrate (casein) solution was incubated with 20 μl of enzyme buffer. The hydrolysis of casein at room temperature was terminated after 15 minutes with the addition of 200 μl of 10% trichloroacetic acid. The hydrolysate was separated from the precipitated protein by centrifugation and its ultraviolet (UV) absorbance at 280nm, as compared to the control, was measured by an 8451A Diode Array Spectrophotometer available from Hewlett Packard. Substrate concentration was such that enyzme activities were directly proportional to the UV absorbances at 280nm reported in Table 2. In this table the values in parentheses represent percentages of initial enzyme activities. The last column in Table 2 shows the calculated half-life of the three enzymes, and it can be seen that the half-life of the mutated [Ser 21 ]aprA gene product is more than three-fold longer than the natural aprA gene product and subtilisin BPN' under the tested conditions. TABLE 2 Thermostability of [Ser 18 ]aprA Gene Product vs. Wild-Type aprA Gene Product and Subtilisin BPN' in O.IM Sodium Glycinate at pH 10.0 Enzyme Activity After Incubation At 52°C For: Half-Life of Protease 0. Hour 1 Hour 2 Hour 3 Hour the Enzyme [Ser 218 ]aprA 0.993 (100%) 0.887 (89%) 0.738 (74%) 0.620 (62%) 4.35 hr Wild-Type aprA 0.132 (100%) 0.702 (62%) 0.437 (38%) 0.252 (22%) 1.37 hr Subtilisin BPN' 0.998 (100%) 0.596 (60%) 0.360 (36%) 0.192 (19%) 1.25 hr Example 8 For determination of thermostability of subtilisins in the presence of detergents, the liquid laundry detergent ERA Plus ® (Procter & Gamble) was used after diluting it with water (1:9) and completely in¬ activating the original protease activity by warming it to 65°C for 30 minutes. The pH of the resultant deter¬ gent solution was 7.50. Using the casein assay and the procedure described in Example 7, the stabilities of ' [Ser 218 ]aprA gene product, wild-type aprA gene product and subtilisin BPN' (Sigma) were tested in the detergent at 45°C. The results are shown in Table 3 in which enzyme activities are expressed as percentages of original enzyme activities. Again, the half-life of the subtilisin analog was on the order of three-fold greater than the natural products under the test conditions. TABLE 3 Thermostability of [Ser 218 ]aprA Gene Product vs. Wild-Type aprA Gene Product and Subtilisin BPN' in Detergent at pH 7.5 Enzyme Activity After Incubation At 45°C For: Half-Life of Protease 0 Hour 0.5 Hour 1.5 Hour 3 Hour the Enzyme [Ser 218 )aprA 100% 93% 82% 71% 6.0 hr Wild-Type aprA 100% 80% 54% 30% 1.73 hr Subtilisin BPN' 100% 84% 62% 38% 2.15 hr The above-tabulated results demonstrate that the [Ser 218 ]-analog of the aprA gene product exhibits greater stability than the wild type aprA gene product or subtilisin BPN' in ERA Plus ® which, with a pH of 7.5, may be described as a cationic to neutral detergent and which most likely has been formulated to be compatible with inclusion of detergent enzymes. These results do not assure, however, that the [Ser 218 ]-aprA gene product will be compatible with all current commercial detergent formulations, e.g., those which have been formulated to the exclusion of detergent enzymes. For example, in preliminary tests with a 2% (w/v) solution of Tide ® , which may be described as an anionic to neutral detergent having a pH of greater than 8.5 and which excludes detergent enzymes in its formulation, the subtilisin BPN' exhibited greater stability than the wild-type and [Ser 218 ]-aprA gene products. The [Ser 218 ]-aprA gene product in that same test, however, showed greater stability than the wild-type aprA gene product. Although the different relative performance of the [Ser 218 ]-aprA gene product and subtilisin BPN' in ERA Plus ® and Tide ® is as yet unexplained, the ex¬ perimental results suggest that proper formulation of detergent compositions is a prerequisite for optimal performance of enzymes included in such compositions. What has been clearly demonstrated is that the [Ser 218 ]- aprA gene product consistently possesses properties superior to those of the wild type aprA gene product, and it is believed that analogs of subtilisins Carlsberg and BPN' according to the present invention will also possess greater stability than the corresponding wild type enzyme. Example 9 Using succinyl-L-alanyl-L-alanyl-L-prolyl-L- phenylalanyl-p-nitroanilide (Vega Biochemicals) as substrate and the rate of increase in absorbance at 405nm due to release of p-nitroaniline [Del Mar, et al.. Anal. Biochem. , 99, 316-320, (1979)] to measure enzyme activity, the thermostabilities of [Ser 218 ]aprA, wild- type aprA and subtilisin BPN' (Sigma) in O.IM sodium phosphate buffer at pH 7.5 were determined as follows. Enzyme solutions of about 0.5 Anson units per liter were incubated at 40°C and 50°C, and at various times aliquots (20 μl) were drawn and diluted into 180 μl of ice-cold 0.1M sodium phosphate buffer at pH 7.5. 10 μl of the thus diluted sample was mixed with 890 μl of ImM succinyl-L-alanyl-L-alanyl-L-prolyl-L- phenylalanyl-p-nitroanilide in 0.1M Tris HC1 pH 8.2 and the absorbances at 405 nm were measured every 15 seconds for 5 minutes on a Hewlett Packard, 8451A Diode Array Spectrophotometer. Residual enzyme activities after various incubation times are expressed in Table 4 and Table 5 as percentages of the corresponding initial activities. The procedure was then repeated in 0.1M sodium phosphate buffer at pH 9.0 and the results are set out in Tables 6 and 7. TABLE 4 Thermostability of [Ser 218 ]aprA Gene Product vs. Wild-Type aprA Gene Product and Subtilisin BPN' in O.IM Sodium Phosphate Buffer at pH 7.5 Enzyme Activity After Incubation at 40°C For: Half Life of Protease 0. Min. 90 Min. 180 Min. 270 Min. the enzyme [Ser 218 ]aprA 100% 92% 87% 81% 13.0 hr 1 Wild-Type aprA 100% 69% 48% 33% 2.8 hr *£> Subtilisin BPN' 100% 48% 26% 14% 1.60 hr 1 TABLE 5 Thermostability of [Ser 218 ]aprA Gene Product vs. Wild-Type aprA Gene Product and Subtilisin BPN' in O.IM Sodium Phosphate Buffer at pH 7.5 Enzyme Activity After Incubation At 50°C For: Half Life of Protease 0 Min. 45 Min. 90 Min. 135 Min. the enzyme [Ser 218 aprA 1 10000%% 8 899%% 8 811%% 71% 4.30 hr Wild-Type aprA 1 10000%% 5 599%% 3 355%% 21% 1.0 hr •c- o Subtilisin BPN' 1 10000%% 3 344%% 1 111%% 4% 0.47 hr TABLE 6 Thermostability of [Ser 18 ]aprA Gene Product vs. Wild-Type aprA Gene Product and Subtilisin BPN' in O.IM Sodium Phosphate Buffer at pH 9.0 Enzyme Activity After Incubation At 40°C For: Half Life of Protease 0 Min. 45 Min. 90 Min. 135 Min. the enzyme [Ser 218 ]aprA 100% 96% 91% 87% 11.5 hr 1 Wild-Type aprA 100% 79% 61% 49% 2.18 hr 4- l__" Subtilisin BPN' 100% 68% 44% 29% 1.25 hr TABLE 7 Thermostability of [Ser 218 ]aprA Gene Product vs. Wild-Type aprA Gene Product and Subtilisin BPN' in O.IM Sodium Phosphate Buffer at pH 9.0 Enzyme Activity After Incubation At 50°C For: Half Life of Protease 0 Min. 20 Min. 40 Min. 60 Min. 80 Min. the enzyme [Ser 218 ]aprA 100% 92% 85% 76% 69% 2.5 hr Wild-Type aprA 100% 61% 36% 23% 14% 0.47 hr Subtilisin BPN' 100% 54% 31% 17% 9% 0.37 hr Example 10 In order to test pH stability of the [Ser 218 ] analog, the procedure of Example 7 was carried out at pH 4.8 and room temperature and the results are set out in Table 8. TABLE 8 Stability of [Ser 218 ]aprA Gene Product vs. Wild-Type aprA Gene Product in 0.1M Sodium Phosphate Buffer at pH 4.8 Half-life of the Protease 0 Hours 4 Days enzyme (days) [Ser 218 ]aprA 100 95% 44.0 Wild-Type aprA 100 47% 3.7 While the present invention has been described in terms of preferred embodiments it is understood that modifications and improvements will occur to those skilled in the art. For example, the sequence Asn-Gly appears at other points in subtilisins, such as at residues 109 and 110 of the aprA gene product and subtilisin BPN 1 and at residues 62 and 63 of subtilisin Carlsberg and of subtilisin DY. Thus, it is expected that substitution of residues other than Asn and Gly at these respective locations may improve stability as well. Similar improvements in stability are expected for such substitutions made in other enzymes which have the Asn-Gly sequence and in other proteins comprising this sequence. Furthermore, it is expected that a subtilisin analog according to the present invention possesses superior properties to wild type subtilisins in detergent formulations such as those disclosed in, for example, U.S. Patent No. 3,732,170; U.S. Patent No. 3,749,671 and U.S. Patent No. 3,790,482, all of which are incorporated by reference herein. Moreover, for practical reasons many industrial processes are conducted at temperatures that are above the stability range of most enzymes. Therefore, although detergent applications have been emphasized herein, it is believed that thermostable proteases according to the present invention are not only advantageous to certain industries such as detergent and hide dehairing, which already require stable proteases, but also may be useful in industries that use chemical means to hydrolyze proteins, e.g. hydrolysis of vegetable and animal proteins for the production of soup concentrates. Therefore, it is intended that the present invention be include all such modifications and improvements as come within the scope of the present invention as claimed. 5 u i e - o u - - - nnex ANNEX Inttmrtontl Application No: PCT/ US87/00027 MICROORGANISMS O≠t ≠tl Steel l" ewHM ien «UΛ tna micreefaanitm nri rreβ lo ex aa««- 13 . ιitv»_..t-i ef the ύ tnwttn • A . l β «ιrπ« CAT ιo«o l -oι*o«rr. Escherichia coli containing plasmid pCFM936 furVHtr ««*««t a are nlentWle* en an eddiαβnal (nee* ri • N*m «< American Type Culture Collection Atm-ntf M luaartafT meβtw-en (including eoeul M on* cauntnr) • 12301 Parklawn Drive Rockville, Maryland 20852 United States of America ACMMMA Nvmkef - 13 January 1986 ATCC 53413 ■. AOemOMAk INOICATIOM* ' (i«« tι«nt It net aaeUcaa ). Thli i eπnatien ι« cofliinuea en t NNW tnacne* *n* f~ "In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 23(4) EPC)." C. O WNATtO »T_.T-» *0" WHICH INDICATION* AM MAO! > (If the meiuuβn. are not lor all .eeifn-led -tate.) D. aiPAMATI PU«MiaHIM β Of INDICATIONS • nee.e »leι>k it net -β-l'-.el.) The .neic-tient ι<»ιe- β ei β w .n M t-emin * 14 me ime'nationai _ure«« laie' • (Soecit* the oeneret natgre el the ιn«ιβa»ιen» •.« " Aeceeeie- Hu an cl D.oo.it "] -■ **ffrΥiMt »neet ««• '«»<•»- »ιtn in. .-ttrnet.on.l ao-Ucat'on βhβn file- (te »e checneα oy in. receiving O fr-i) (Autnβ'ite* 0"i«!erl Tne ««te e' ,«< »ιe' ("« ■ » me .conce t) 6j in. imernetienel *w»ey '• o«I (A-ineniee O*«e t *CTΛOΠJ- (jaawr t*m)

Claims: WHAT IS CLAIMED IS: 1. An analog of a Bacillus subtilisin, said Bacillus subtilisin having an amino acid sequence comprising an Asn-Gly sequence, wherein one or both residues of said Asn-Gly sequence are deleted or are replaced by a residue of a different amino acid. 2. The analog as recited in claim 1 wherein an asparaginyl residue in said Asn-Gly sequence is replaced by a residue of a different amino acid. 3. The analog as recited in claim 1 wherein an asparaginyl residue in said Asn-Gly sequence is replaced by a residue of an amino acid from the group consisting of serine, valine, threonine, cysteine, glutamine and isoleucine. 4. The analog as recited in claim 3 wherein said asparaginyl residue in said Asn-Gly sequence is replaced by serine. 5. An analog of a Bacillus subtilisin having an amino acid sequence wherein an asparginyl residue naturally occurring at a position corresponding to posi¬ tion 218 in the amino acid sequence disclosed in Table 1 is replaced by a residue of a different amino acid. 6. The analog as recited in claim 5 wherein an asparaginyl residue at said position is replaced by a residue of an amino acid from the group consisting of serine, valine, threonine, cysteine, glutamine and isoleucine. SUBSTITUTE SHEET 7. The analog as recited in claim 6 wherein a seryl residue replaced said asparaginyl residue. 8. The analog as recited in claim 5 wherein said analog is an analog of a naturally occurring Bacillus subtilisin in a strain selected from the group consisting of subtilisin Carlsberg, subtilisin DY, subtilisin BPN' and aprA gene product. 9. The analog as recited in claim 8 wherein all residues except the residue at position 218 comprise amino acid residues as disclosed in Table 1. 10. A nucleic acid encoding an analog of Bacillus subtilisin, said Bacillus subtilisin having an amino acid sequence comprising an Asn-Gly sequence, wherein codons which encode one or both residues of said Asn-Gly sequence are deleted or are replaced by codons encoding a different amino acid residue. 11. The nucleic acid as recited in claim 10 encoding a polypeptide wherein an asparaginyl residue at a position corresponding to position 218 in the amino acid sequence disclosed in Table 1 is replaced by a residue of a different amino acid. 12. The nucleic acid as recited in claim 11 wherein said different amino acid is a member of the group consisting of serine, valine, threonine, cysteine, glutamine and isoleucine. 13. The nucleic acid as recited in claim 12 wherein said residue at said position comprises a seryl residue. 14. The nucleic acid as recited in claim 13 wherein all amino acid residues at all positions in said amino acid sequence of said analog except position 218 comprise amino acid residues as disclosed in Table 1. 15. A system for the production of an analog of a Bacillus subtilisin comprising: a host cell; and nucleic acid, within said host cell, encoding an analog of subtilisin having an amino acid sequence wherein a residue at a position corresponding to position 218 in the amino acid sequence disclosed in Table 1 does not comprise an asparaginyl residue. 16. The system as recited in claim 15 wherein said residue at said position comprises a residue of an amino acid from the group consisting of serine, valine, threonine, cysteine, glutamine and isoleucine. 17. The system as recited in claim 16 wherein said residue at said position comprises a seryl residue. 18. The system acid as recited in claim 17 wherein all residues at all positions except 218 comprise amino acid residues as disclosed in Table 1. 19. The system as recited in claim 18 wherein said host cell is deficient in secreted proteases other than subtilisin. 20. The system as recited in claim 15 wherein said nucleic acid is extrachromosomal. 21. The system as recited in claim 18 wherein said nucleic acid is chromosomal. 22. A method for improving the thermal and pH stability of a Bacillus subtilisin having an amino acid sequence comprising an Asn-Gly sequence comprising the step of replacing- a residue in said Asn-Gly sequence with a residue of a different amino acid. 23. The method as recited in claim 22 wherein said residue is the asparaginyl residue at the position in the amino acid sequence of the Bacillus subtilisin which corresponds to position 218 in the amino acid sequence as disclosed Table 1. 24. A method for improving the. thermal and pH stability of a Bacillus subtilisin having an amino acid sequence comprising an Asn-Gly sequence comprising the step of deleting a residue in said Asn-Gly sequence. 25. A detergent formulation comprising an analog of a Bacillus subtilisin, said Bacillus subtilisin having an amino acid sequence comprising an Asn-Gly sequence, wherein one or both residues of said Asn-Gly sequence are deleted or are replaced. 26. An analog of a Bacillus subtilisin, said analog having an amino acid sequence with fewer Asn-Gly sequences than are present in said Bacillus subtilisin.

Inventors: STABINSKY YITZHAK, ZUKOWSKI MARK M, STABINSKY, YITZHAK, ZUKOWSKI, MARK, M.
Applicants: AMGEN
Application year: 1987
Main classification: C12N9
IPC codes: C11D3, C12N1, C12N9, C12N15, C12P21, C12R1